AlphaCentric Advisors’s ADC Therapeutics ADCT Stock Holding History

AlphaCentric Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,068,468	Closed	-$958K	–	217
2023 Q3	$958K	Buy	1,068,468 +290,468	+37%	+$386K	0.54%	65
2023 Q2	$1.67M	Buy	778,000 +18,000	+2%	+$40.5K	0.93%	39
2023 Q1	$1.48M	Buy	760,000 +462,500	+155%	+$1.71M	1.02%	23
2022 Q4	$1.14M	Buy	+297,500	New	+$1.19M	1.13%	27
2021 Q3	–	Sell	-26,000	Closed	-$633K	–	196
2021 Q2	$633K	Buy	26,000 +9,000	+53%	+$209K	0.17%	49
2021 Q1	$415K	Buy	17,000 +13,500	+386%	+$391K	0.14%	53
2020 Q4	$112K	Buy	3,500 +2,500	+250%	+$81.9K	0.05%	112
2020 Q3	$33K	Buy	+1,000	New	+$43.3K	0.02%	127

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

AlphaCentric Advisors's ADCT Position: Q4 2023 in Review

AlphaCentric Advisors sold out of ADC Therapeutics (ADCT) in Q4 2023, closing a stake of 1,068,468 shares — an estimated $958K sold.

AlphaCentric Advisors first reported a position in ADCT in Q3 2020 and held it in 8 quarters. The position peaked at $1.67M in Q2 2023. 37 funds tracked by Wall St. Rank hold ADCT as of Q4 2023.

AlphaCentric Advisors reported no remaining ADC Therapeutics position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 1,068,468 ADC Therapeutics shares in Q4 2023, an estimated $958K.
AlphaCentric Advisors first reported a position in ADC Therapeutics in Q3 2020 and held it in 8 quarters.
AlphaCentric Advisors's ADC Therapeutics position peaked at $1.67M in Q2 2023.
37 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.